Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Glaxo and Teva settle Lamictal suit
The terms of the settlement, which remain subject to government review, provide that Teva may, under an exclusive royalty-bearing license from GSK, and on a date not later
The terms of the settlement, which remain subject to government review, provide that Teva may, under an exclusive royalty-bearing license from GSK, and on a date not later
The goals of the project are to identify and optimize A2A antagonist compounds as therapeutic candidates for Parkinson’s disease and to evaluate these novel compounds in the laboratory.
HIV infection and HIV medications are both associated with the development of neuropathy and neuropathic pain. Symptoms include burning sensations and numbness, which are similar to the neuropathies
In January, Provenge failed to achieve its primary endpoint in another phase III trial, sending Dendreon’s shares down by close to 27%. In the recent trial, however, the
UCB Pharma submitted the pediatric supplemental new drug application (sNDA) for Keppra on December 20, requesting approval of Keppra (levetiracetam) for the adjunctive treatment of partial seizures in
The two-year Tsyabri (natalizumab) AFFIRM monotherapy trial achieved the two-year primary endpoint of slowing the progression of disability in patients with relapsing forms of multiple sclerosis (MS). Tsyabri
Eligard (leuprolide acetate for injectable suspension) is already approved for one-month (7.5mg), three-month (22.5mg) and four-month (30mg) formulations and Eligard 45mg was approved by the FDA on December
The investigational drug, avanafil, is a highly selective, orally administered phosphodiesterase type 5 (PDE5) inhibitor being developed by the company to treat erectile dysfunction (ED). The trial is
As part of the investment in Gamida-Cell in 2003, Teva held an option to jointly complete the development and globally commercialize StemEx. Teva will invest, under certain conditions,
The candidate is one of multiple compounds from Affinium’s Galapagos program and has been selected for its potential as an intravenous and oral antibiotic against hospital and community